Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desvenlafaxine
Drug ID BADD_D00621
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults[A6990,A6991,Label].
Marketing Status approved; investigational
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D07793
MeSH ID D000069468
PubChem ID 125017
TTD Drug ID D0O3FG
NDC Product Code 63304-191; 0054-0401; 0054-0603; 14501-0068; 70436-013; 70771-1311; 68382-469; 0054-0400; 70436-036; 70771-1312; 0591-3660; 71335-1815; 68382-105; 46708-152; 70518-3195; 69766-025; 60687-607; 63304-192; 70771-1661; 68382-741; 72888-144; 46708-153; 53002-1801; 71335-1753; 71335-1975; 72888-143; 63629-7524; 70436-012; 0591-3659; 71335-1700; 0591-4060; 50090-4806
UNII NG99554ANW
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C16H25NO2
CAS Registry Number 93413-62-8
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Feeling hot08.01.09.009--Not Available
Feeling jittery08.01.09.0160.001908%Not Available
Flat affect19.04.01.004--Not Available
Food poisoning12.03.01.024; 11.07.02.001; 07.11.01.0070.000392%Not Available
Gait disturbance17.02.05.016; 08.01.02.002; 15.03.05.013--
Gastrointestinal disorder07.11.01.0010.001836%Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal pain07.01.05.0050.000392%
Generalised tonic-clonic seizure17.12.01.0020.000178%Not Available
Glaucoma06.03.01.0020.000357%
Glossodynia07.14.02.0010.000392%Not Available
Haemorrhagic disorder01.01.03.004; 24.07.01.021--Not Available
Hallucination19.10.04.0030.000802%
Hallucination, auditory19.10.04.0040.000535%Not Available
Hallucinations, mixed19.10.04.0080.000178%Not Available
Head discomfort17.02.05.0270.000392%Not Available
Headache17.14.01.0010.014995%
Hepatic failure09.01.03.0020.000267%
Hiccups22.12.01.001; 07.01.06.0090.000392%
Hostility19.05.01.0030.000392%Not Available
Hyperaesthesia17.02.06.004; 23.03.03.0800.000392%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.0280.004564%
Hypersensitivity10.01.03.003--
Hypersomnia19.02.05.001; 17.15.01.0010.000998%
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023; 23.03.03.0810.001480%Not Available
Hypomania19.16.02.001--Not Available
Hyponatraemia14.05.04.0020.001765%
Immune system disorder10.02.01.001--Not Available
Inappropriate affect19.04.01.0050.000267%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 11 Pages